Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Press Releases
Office Support
Provider Manual
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

October 2011

Specialty Pharmacy Program additions 

The following have been added to Harvard Pilgrim’s Specialty Pharmacy Program.

Name Indication Coverage Available From
irazyr (icatibant injection) Firazyr is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Firazyr provides a new option to treat acute attacks of HAE because it is the first HAE treatment that can be self-administered. Pharmacy benefit Curascript Pharmacy
Xalkori (crizotinib) Xalkori is indicated to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK) gene. (Xalkori’s companion diagnostic test, the Vysis ALK Break Apart FISH Probe Kit, tests for the ALK gene.) Pharmacy benefit (quantity limit of 60 tablets/30 days) Curascript Pharmacy
Zelboraf (vemurafenib) Zelboraf is indicated to treat patients with late-stage (metastatic) or unresectable melanoma. Zelboraf is specifically indicated for the treatment of patients with melanoma whose tumors express a gene mutation called BRAF V600E. (Zelboraf’s companion diagnostic test, the cobas 4800 BRAF V600 Mutation Test, tests for the BRAF V600E mutation.) Pharmacy benefit Curascript Pharmacy
Nulojix (belatacept) Nulojix is indicated to prevent acute rejection in adult patients who have had a kidney transplant. Medical benefit ICORE Healthcare
H.P. Acthar Gel (repository corticotropin injection) H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue used to treat infantile spasms, multiple sclerosis exacerbations, and nephrotic syndrome. Medical benefit Curascript Pharmacy

For more information, please visit Harvard Pilgrim’s Specialty Pharmacy Program page.

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version


Harvard Pilgrim #1 for eighth year in a row

MA medical directors’ meeting focuses on resources to support patient care

Medicare product updates

Real-time HIPAA 270/271 transactions now available on HPHConnect

ICD-10 provider preparedness survey

Coming this month: New IVR phone system

HIPAA 5010 EDI transaction testing and production reminder


Diabetes case listing

QuitWorks offers free nicotine patches

Mental health screening in the primary care setting

Fosamax Plus D tier change

Reminder: Order Synagis in time for RSV season

Specialty Pharmacy Program additions


Policy change: Reimbursement for epidural steroid injections

Billing update: Antepartum E&M beyond standard global obstetrical visits

Billing reminder: Confirmation of pregnancy E&M visits

2012 CPT and HCPCS codes

EDI update: Harvard Pilgrim’s new benefit adjudication system

Multiple payment policy changes: Covered clinical indications


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network and Product Development

Joann Peck,
Provider Communications Manager

Brian E. O'Neill,

Kristin Edmonston,
Production Coordinator